SAS, a data and AI software specialist, has bolstered its capabilities in the life sciences sector with its Clinical Acceleration Repository program.
The technology supports those in the R&D space with their audit and administration, as well as assisting in managing clinical research data to allow pharmaceutical companies to expedite their clinical trials through to regulatory submission.
Streamlining and securing clinical data
Getting the most out of clinical data requires the establishment a secure location for the its management, as well as the incorporation of various sources to gain a better understanding of what’s been found from trials.
SAS’ Clinical Acceleration Repository provides this, according to the company; the technology provides a modular, open, cloud-native content repository for managing, reporting and reviewing data.
The unique benefits of SAS Clinical Acceleration Repository include:
- Access to curated research information and health data through a single system of record
- A production-ready data repository that enables easier and faster data validation
- A multi-lingual, open environment to support use of third-party programming languages and tools/data integration from many locations and sources
Access to SAS Viya enabled solutions and technology
“SAS Clinical Acceleration Repository enables researchers and data scientists to better manage their clinical data and empowers organisations to make informed business decisions,” said Vice President of Healthcare and Life Sciences at SAS, Gail Stephens.
“Accelerating and improving the clinical development process helps bring therapies to market sooner and strengthens the bottom line for life sciences and health organisations.”
